Eli Lilly and Company (LLY)vsBiomotion Sciences Ordinary Shares (SLXN)
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
SLXN
Biomotion Sciences Ordinary Shares
$4.67
-5.85%
HEALTHCARE · Cap: $1.28M
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SLXN
Avoid18
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SLXN
SLXN has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : SLXN
The primary concerns for SLXN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while SLXN is a value play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.48 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 18/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Biomotion Sciences Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Biomotion Sciences (SLXN) is a pioneering biotechnology company focused on regenerative medicine, committed to developing innovative therapies for severe medical conditions with substantial unmet needs. The company boasts a strong pipeline of product candidates aimed at transforming patient care and outcomes. With strategic partnerships enhancing its research and development efforts, Biomotion Sciences is strategically positioned to make significant contributions to the biotechnology sector, making it an attractive investment opportunity for institutional investors interested in advanced therapeutic solutions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?